- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | FluoGuide A/S Publishes Interim Report Q3 2025 | 191 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 27, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO) today releases its results for the period 1 January - 30 September 2025. The Q3 report is... ► Artikel lesen | |
| 25.11. | FluoGuide A/S: FluoGuide Signs Collaboration Agreement with ZEISS | 244 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 25, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 25 November 2025 - FluoGuide A/S, a biotech company specializing in precision cancer surgery, announces... ► Artikel lesen | |
| 24.11. | Minutes from Extraordinary General Meeting in FluoGuide A/S | 174 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company" held an extraordinary general meeting on 24 November 2025.To the shareholders of FluoGuide... ► Artikel lesen | |
| 24.11. | Invitation to FluoGuide A/S Webcast on 27 November 2025 | 201 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025.The following event will take place... ► Artikel lesen | |
| 05.11. | FluoGuide A/S: FluoGuide Strengthens Leadership to Advance Clinical Program and Regulatory Approval Strategy | 258 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces changes to both its... ► Artikel lesen | |
| 05.11. | FluoGuide A/S: FluoGuide Convenes an Extraordinary General Meeting | 219 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") hereby invites shareholders to participate in an extraordinary general meeting to be... ► Artikel lesen | |
| 03.11. | FluoGuide A/S Issue Warrants to Board Members, Executive Management and Employees | 254 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / November 3, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") announces that it has issued 199,000 warrants to members of the board directors, members... ► Artikel lesen | |
| FLUOGUIDE Aktie jetzt für 0€ handeln | |||||
| 03.11. | FluoGuide A/S Completes Directed Share Issue of SEK 104 Million | 280 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER... ► Artikel lesen | |
| 03.11. | FluoGuide A/S Intends to Carry Out a Directed Share Issue of Approximately SEK 100 Million | 233 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER... ► Artikel lesen | |
| 28.10. | FluoGuide A/S: FluoGuide in Advanced Negotiations on Collaboration Agreement with a World Leading Medical Technology Company | 158 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / October 28, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company specializing in precision cancer surgery, announces to be in advanced... ► Artikel lesen | |
| 16.09. | FluoGuide A/S: FluoGuide Receives Positive FDA Feedback on FG001 in High-Grade Glioma | 240 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / September 16, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") received positive feedback and alignment with the FDA at a pre-IND consultation on its U.S. clinical... ► Artikel lesen | |
| 28.08. | FluoGuide A/S Publishes Interim Report H1 2025 | 197 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / August 28, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 28 August 2025 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period... ► Artikel lesen | |
| 22.08. | Invitation to FluoGuide A/S Webcast on 28 August 2025 | 262 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / August 22, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q2 2025 on Thursday 28 August 2025.The following event will take place later... ► Artikel lesen | |
| 21.07. | FluoGuide A/S: FluoGuide Enters Collaboration with Global MedTech Company Olympus | 495 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / July 21, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces a collaboration with... ► Artikel lesen | |
| 03.07. | FluoGuide A/S: Update on 2025 Outlook and Company progress | 274 | GlobeNewswire (Europe) | Copenhagen, Denmark, 3 July 2025 - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision cancer surgery, is pleased to share an update on the 2025 Outlook... ► Artikel lesen | |
| 10.06. | FluoGuide A/S: FG001 clinical data in High-Grade Glioma is now published in Neurosurgery | 600 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / June 10, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision... ► Artikel lesen | |
| 28.05. | FluoGuide A/S: FluoGuide A/S publishes interim report for the period January - March 2025 - On track - first patients enrolled in CT-005 | 216 | GlobeNewswire (Europe) | Copenhagen, Denmark, 28 May 2025 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 31 March 2025. The Q1 report is available as an attached document... ► Artikel lesen | |
| 15.04. | FluoGuide A/S: FluoGuide includes first patient in phase II trial of FG001 for head and neck cancer | 217 | GlobeNewswire (Europe) | Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, is pleased to announce the inclusion of the first patient in its phase... ► Artikel lesen | |
| 27.03. | Minutes from Annual General Meeting in FluoGuide A/S | 329 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 27, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company" held its annual general meeting on 27 March 2025.To the shareholders of FluoGuide A/S.The... ► Artikel lesen | |
| 12.03. | Notice of Annual General Meeting in FluoGuide A/S | 386 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / March 12, 2025 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39 29 64... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 46,860 | +1,06 % | Fresenius Kabi Expands Simplist Portfolio of Prefilled Syringes | ||
| FRESENIUS MEDICAL CARE | 40,900 | +0,47 % | Neue 3,250%-Anleihe von Fresenius Medical Care | Stuttgart (www.anleihencheck.de) - Fresenius Medical Care (ISIN DE0005785802/ WKN 578580) hat eine Unternehmensanleihe (ISIN XS3233499089/ WKN A460DH) mit einem Volumen von bis zu 500 Millionen Euro... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 35,140 | 0,00 % | BMO Capital Maintains Bullish 12%+ BrightSpring EBITDA Growth Outlook on Drug Contract Wins, Generic Conversions | ||
| ALIGNMENT HEALTHCARE | 19,090 | +0,05 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 42,520 | -0,16 % | EQS-DD: Siemens Healthineers AG: Elisabeth Staudinger-Leibrecht, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
28.11.2025 / 17:23... ► Artikel lesen | |
| GENEDX | 160,60 | -1,84 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 29,530 | -2,86 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,000 | -0,25 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| PROGYNY | 24,950 | -1,27 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| GERRESHEIMER | 25,620 | -4,12 % | INDEX-MONITOR: JPMorgan erwartet Aumovio im MDax - Dax wohl unverändert | FRANKFURT (dpa-AFX) - Im Dax dürfte zur Index-Überprüfung an diesem Mittwoch alles beim Alten bleiben. Eine Änderung erwartet die US-Bank JPMorgan dagegen im Index der mittelgroßen Unternehmen, die... ► Artikel lesen | |
| BETA BIONICS | 28,440 | -3,50 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 42,940 | -0,88 % | EQS-AFR: Carl Zeiss Meditec AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Carl Zeiss Meditec AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Carl Zeiss Meditec AG: Vorabbekanntmachung... ► Artikel lesen | |
| ADAPTHEALTH | 9,430 | 0,00 % | AdaptHealth: Strategische Expansion und Technologie-Investitionen als Wachstumstreiber | ||
| PACS GROUP | 31,460 | 0,00 % | PACS Group, Inc. - 8-K, Current Report | ||
| NEUROPACE | 16,020 | +2,50 % | NeuroPace, Inc.: NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases | MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued... ► Artikel lesen |
FLUOGUIDE A/S gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 3,190 Euro und damit +2,24 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLUOGUIDE A/S finden Sie auf Wallstreet Online.